In this webinar, presented by Dr Hood Thabit, please join us as we discuss post-prandial hyperglycaemia specifically
- To give a clear understanding of recent pump developments
- To demonstrate NICE guidelines on indications for pump therapy
- To explain the clinical evidence and practical benefits of pump therapy vs. MDI (multiple daily injections)
- To provide evidence of the benefits of using Lyumjev®▼ (insulin lispro) in pump therapy using case studies
This presentation will include a 20 minute Q&A session.
Lilly have sponsored the content of this meeting in partnership with ABCD. The speaker has been selected, briefed and paid honorarium by Lilly. Lilly products will be discussed at this meeting
Please click the following link for Lyumjev®▼ (insulin lispro) PI and AE reporting: www.lillydiabetes.co.uk/assets/pdf/lyumjev_pi.pdf
Lyumjev is indicated for the treatment of diabetes mellitus in adults only. Lyumjev is not indicated for use in children. Lyumjev is not available in Ireland.
Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446.
Lyumjev® and Lilly are registered trademarks of Eli Lilly and Company
PP-UR-GB-0325 February 2022